Defects in the DNA mismatch repair proteins result in @entity124 and @entity5 in @entity14 ( @entity14 ). However, the role of mismatch repair (MMR) proteins and @entity124 ( @entity124 ) in transitional cell @entity150 is less clear. In our study, the expression of 2 MMR proteins and the frequency of @entity150 ( @entity8214 ) were investigated. One hundred eleven @entity1 with @entity8214 of the bladder were studied, with complete clinicopathological data (median follow up of 5 years, range 5-16 years). Immunohistochemistry was used to detect the expression levels of @entity6756 and @entity4311 . Microsatellite analysis for 14 loci (10 loci from the Bethesda consensus panel and the repeats in the TGFbetaR2, @entity589 , @entity23151 and @entity4638 genes) was performed on 84 @entity5 . Reduced expression of either MMR protein was seen in 26 of 111 @entity5 (23%). Reduced expression was seen more commonly in muscle invasive (p<0.03) and high grade @entity8214 (p<0.03) than in superficial, low grade @entity5 . By 5 years, reduced expression of either MMR protein was associated with fewer recurrences of superficial @entity5 (p=0.015) and fewer relapses in all @entity5 (p=0.03), compared to @entity5 with normal expression. Nine @entity5 had reduced expression of both MMR proteins, analysis which suggests a synergistic reduction in expression (p=0.001). MMR expression was related to @entity1 age, younger @entity1 being more likely to have reduced MMR expression than older @entity1 (p<0.01). @entity124 was seen at multiple loci in 1 @entity5 (1%) and at a single locus in 6 @entity5 (7%). @entity124 was not associated with MMR expression. Our findings indicate that reduced expression of the MMR proteins may have an important contribution in the development of a subset of TCCs and suggest a potential role for MMR expression as prognostic indicators.

Differential expression of @entity6756 and @entity4311 is related to @entity150 grade, stage and prognosis but not XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6756 :: ('4292', 'Gene') :: ['hMLH1'] @entity8214 :: ('MESH:C536943', 'Disease') :: ['TCC'] @entity124 :: ('MESH:D053842', 'Disease') :: ['MSI', 'microsatellite instability'] @entity589 :: ('581', 'Gene') :: ['BAX'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancy', 'tumors'] @entity4311 :: ('4436', 'Gene') :: ['hMSH2'] @entity150 :: ('MESH:D001749', 'Disease') :: ['MSI in Transitional cell carcinoma of the bladder', 'carcinoma of the bladder'] @entity23151 :: ('4437', 'Gene') :: ['hMSH3'] @entity14 :: ('MESH:D015179', 'Disease') :: ['hereditary non-polyposis colorectal carcinoma', 'HNPCC'] @entity4638 :: ('2956', 'Gene') :: ['hMSH6']
@entity124 :: (MESH:D053842,Disease) :: ['microsatellite instability']
